Menu Search
Equities

Xeris Biopharma Holdings Inc

XERS:NSQ

Xeris Biopharma Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.09
  • Today's Change0.05 / 1.64%
  • Shares traded535.93k
  • 1 Year change+77.59%
  • Beta1.8068
Data delayed at least 15 minutes, as of Nov 22 2024 20:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Xeris Biopharma Holdings Inc grew revenues 48.68% from 110.25m to 163.91m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -94.66m to -62.26m.
Gross margin81.36%
Net profit margin-33.69%
Operating margin-25.54%
Return on assets-19.45%
Return on equity--
Return on investment-26.81%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Xeris Biopharma Holdings Inc fell by 54.64m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 47.02m for operations while cash used for investing totalled 6.00m.
Cash flow per share-0.3539
Price/Cash flow per share--
Book value per share-0.1901
Tangible book value per share-1.03
More ▼

Balance sheet in USDView more

Xeris Biopharma Holdings Inc has a Debt to Total Capital ratio of 113.96%, a lower figure than the previous year's 4,926.85%.
Current ratio1.79
Quick ratio1.29
Total debt/total equity--
Total debt/total capital1.14
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.